Dermata Therapeutics (DRMA)

Executive Summary

Dermata Therapeutics (NASDAQ: DRMA) is a clinical-stage biotechnology company developing novel treatments for inflammatory skin diseases using its proprietary Spongilla technology platform. The platform is derived from a naturally sourced freshwater sponge and offers a dual mechanism of action targeting multiple disease pathways. The company's lead candidate, DMT310, is being evaluated in clinical trials for moderate-to-severe acne and rosacea, with the potential to address significant unmet needs in these large markets. A second candidate, DMT410, utilizes the same sponge material in a different formulation for topical delivery and is being investigated for aesthetic indications, such as reducing submental fat, and medical conditions including psoriasis and primary axillary hyperhidrosis. As a public company, Dermata is focused on advancing its pipeline through clinical development and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 data readout for DMT310 in moderate-to-severe acne60% success
• Q3 2026Phase 2 data readout for DMT410 in primary axillary hyperhidrosis50% success
• TBDPotential partnership or licensing deal for DMT310 or DMT41040% success